EMEA-002940-PIP02-21
Key facts
| Active substance |
Molnupiravir
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0553/2021
|
| PIP number |
EMEA-002940-PIP02-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Prevention of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
|
| Contact for public enquiries |
Merck Sharp & Dohme (Europe), Inc.
E-mail: pip.information@merck.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|